A main controller of an immunological test apparatus counts an elapsed time TP. An information output unit outputs required determination time information regarding a required determination time so as to be associated with information of a determination result. The required determination time information is at least information indicating that the elapsed time TP exceeds a set time TS at which sensitization processing, in which a chemical solution for sensitizing the coloration state of a reagent that is combined with influenza virus to be colored is spread onto a carrier, is started, that is, information indicating that the sensitization processing has been performed.

Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.

The present invention relates to a binding molecule having neutralizing activity against Middle East Respiratory Syndrome-Coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having strong ability to bind to an S protein of MERS-CoV and neutralizing activity against MERS-CoV and thus being very useful in the prevention, treatment or diagnosis of MERS-CoV infection.

The invention aims to carry out an immunoassay method for a respiratory tract virus, wherein non-specific reaction is suppressed. The object can be achieved by an immunoassay method for a respiratory tract virus, the method comprising: (A) bringing a biological sample that may contain a respiratory tract virus into contact with an anionic surfactant; (B) bringing the respiratory tract virus into contact with a conjugate, to forma first complex; (C) bringing the first complex into contact with an antibody immunologically reactive with the respiratory tract virus, to forma second complex; and (D) measuring a signal derived from the conjugate.

The composition includes a first construct having a first portion of a protein and a first antigen-recognizing amino acid sequence; and a second construct having a second portion of the protein that catalyzes a reaction when combined with the first portion of the protein and a second antigen-recognizing amino acid sequence. The first and second synthetic constructs include a sulfhydryl group configured such that a disulfide bond is formed between the first and second synthetic constructs when the first antigen-recognizing amino acid sequence and the second antigen-recognizing amino acid sequence bind an antigen.

Devices and materials are disclosed for collecting breath samples and for testing such samples for the presence of a pathogen, for example the pathogen(s) associated with Coronavirus Disease 2019 (COVID-19). In some embodiments, a collection device can include a tube into which a subject can exhale or cough, and that provides for use of a filter to capture expired sample material. In some embodiments, a sample liquid can be created from the breath sample by addition of an indicator to render a pathogen in the sample readily detectable. In some embodiments, materials are provided for an assay to detect a pathogen in the sample liquid.

Described herein are blocking agents that can be used in diagnostic assays to prevent false positive results.

Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.

Disclosed are a novel immunoassay format design for determining a total antibody, and a kit accordingly provided for detecting antibodies of a pathogen or pathogens of infectious diseases within a human blood sample, wherein the kit comprises: a first reagent containing at least one antigen coated on a solid phase support and an anti-human IgM antibody coated on a solid phase support; and a second reagent containing at least one labelled antigen and a labelled anti-human IgG antibody, wherein at least one antigen of the at least one antigen coated on a solid phase support and at least one antigen of the at least one labelled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. The kit can overcome the disadvantages caused by detection principles while retaining the advantages of each detection principle. In addition, also provided is a new method for detecting an antibody produced after the infection of a pathogen or pathogens in a sample.

A secure assay device is disclosed herein that provides: an assay or a test device that provides at least one result, wherein the assay or test device comprises at least one surface which exhibits optical change in response to at least one target particle, at least one marker or a combination thereof; and at least one multi-layer coating that at least partially covers the assay membrane, the assay device or a combination thereof, wherein the multi-layer coating blocks or impairs the user visualization of the optical change, the at least one result or a combination thereof. A secure reader and method of utilizing the secure assay device and secure reader are disclosed herein.